A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 26 Jun 2012
At a glance
- Drugs Capecitabine; Docetaxel; Gemcitabine; Paclitaxel; Sunitinib; Vinorelbine; Vinorelbine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Aug 2011 Actual end date Jun 2011 added as reported by ClinicalTrials.gov.
- 01 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History